LEXXW - Lexaria Announces Issuance of Options
(TheNewswire)
Kelowna, British Columbia– TheNewswire – June 8, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the“Company” or “Lexaria”), a global innovator in drug deliveryplatforms announces the issuance of 87,935 stock options.
Stock Option Issuance
Lexaria announces that on June 8,2021 it has issued an aggregate 87,935 stock options to a total ofnine directors, officers, employees and consultants bearing anexercise price of US$7.08 for a period of five years ending June 8,2026 (collectively the “Options”). The Options were issuedpursuant to the Company’s registered Incentive Equity Plan and willbear a restrictive hold period, ending on October 9, 2021, as requiredpursuant to the policies of the Canadian Securities Exchange.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. DehydraTECH has repeatedly demonstrated since 2016 withcannabinoids and nicotine the ability to increase bio-absorption by upto 5-10x, reduce time of onset from 1 - 2 hours to minutes, and maskunwanted tastes; and is planned to be further evaluated for orallyadministered bioactive molecules, including anti-virals, cannabinoids,vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), andnicotine. Lexaria has licensed DehydraTECH to multiple companiesincluding a world-leading tobacco producer for the development ofsmokeless, oral-based nicotine products and for use in industries thatproduce cannabinoid beverages, edibles, and oral products. Lexariaoperates a licensed in-house research laboratory and holds a robustintellectual property portfolio with 18 patents granted andapproximately 60 patents pending worldwide. For more information,please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatoryapprovals, managing and maintaining growth, the effect of adversepublicity, litigation, competition, scientific discovery, the patentapplication and approval process, potential adverse effects arisingfrom the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the US Securities and Exchange Commission on EDGAR. Thereis no assurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-looking statements contained herein, whether as a resultof any new information, future events, changed circumstances orotherwise, except as otherwise required by law.
TheCSE has not reviewed and does not accept responsibility for theadequacy or accuracy of this release.
INVESTOR CONTACT:
Copyright (c) 2021 TheNewswire - All rights reserved.